Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib as 2nd Line Therapy for CP-CML
NCT03807479Phase 2Terminated
- Sponsor
- GWT-TUD
- Start
- Dec 2018
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ponatinib in chronic myeloid leukemia (CML), sponsored by GWT-TUD. Started Dec 2018; status: terminated.
02
Drugs
ponatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03807479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03807479.